Related Experiment Video
Updated: Oct 22, 2025
12:56
Methodology for Biomimetic Chemical Neuromodulation of Rat Retinas with the Neurotransmitter Glutamate In Vitro
Published on: December 19, 2017
7.9K
Therapy Approaches for Stargardt Disease.
Elena Piotter1,2, Michelle E McClements1,2, Robert E MacLaren1,2
1Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DU, UK.
Biomolecules
|August 27, 2021
Summary
Stargardt disease, a leading cause of inherited childhood blindness, faces unique challenges. This review explores diverse therapeutic strategies, including gene therapy and genome editing, for Stargardt disease patients.
Area of Science:
- Ophthalmology
- Genetics
- Retinal Diseases
Background:
- Stargardt disease is the most common inherited retinal disease causing childhood blindness.
- It has an early onset and progresses throughout an individual's life.
- Its unique etiology presents challenges not seen in other inherited retinal diseases like choroideremia.
Purpose of the Study:
- To review current pre-clinical and clinical trial data for Stargardt disease treatments.
- To explore diverse therapeutic strategies for Stargardt disease.
- To assess the potential of emerging technologies like CRISPR for Stargardt disease therapy.
Main Methods:
- Review of recent pre-clinical research.
- Analysis of ongoing clinical trial data.
- Examination of various therapeutic modalities including small molecules, antisense oligonucleotides, viral gene supplementation, cell replacement, and genome editing.
Main Results:
- A spectrum of therapeutic strategies is being investigated for Stargardt disease.
- Emerging technologies like CRISPR-based genome editing show promise.
- Despite challenges, progress is being made towards effective treatments.
Conclusions:
- Stargardt disease requires innovative therapeutic approaches due to its complex etiology.
- Multiple treatment strategies are under investigation, offering hope for patients.
- Advancements in gene therapy and genome editing are critical for future Stargardt disease treatments.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
765
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
765
01:28Angle Closure Glaucoma: Treatment
896
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
896
01:25Glaucoma: Overview
994
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
994
01:22Alzheimer's Disease: Treatment
324
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
324
01:22iPS Cell Differentiation
2.9K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.9K